三阴性乳腺癌新辅助治疗的治疗模式与进展
Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
作者信息
Xiao Yan, Gao Wencheng
机构信息
Department of Oncology, Dongguan Tungwah Hospital, Dongguan, Guangdong 523000, P.R. China.
Department of General Surgery, Dongguan Houjie Town People's Hospital, Dongguan, Guangdong 523962, P.R. China.
出版信息
Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340. eCollection 2022 Jul.
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous disease, accounting for about 15.0-20.0% of all breast cancer cases. TNBC is associated with early recurrence and metastasis, strong invasiveness and a poor prognosis. Chemotherapy is currently the mainstay of treatment for TNBC, and achievement of a pathological complete response is closely associated with a long-term good prognosis. Improving the long-term prognosis in patients with TNBC is a challenge in breast cancer treatment, and more clinical evidence is needed to guide the choice of treatment strategies. The current study reviews the conventional treatment modality for TNBC and the selection of neoadjuvant chemotherapy (NACT) regimens available. The research progress on optimizing NACT regimens is also reviewed, and the uniqueness of the treatment of this breast cancer subtype is emphasized, in order to provide reference for the clinical practice and research with regard to TNBC treatment.
摘要
三阴性乳腺癌（TNBC）是一种异质性疾病，约占所有乳腺癌病例的15.0-20.0%。TNBC与早期复发和转移、强侵袭性及不良预后相关。化疗是目前TNBC的主要治疗手段，实现病理完全缓解与长期良好预后密切相关。改善TNBC患者的长期预后是乳腺癌治疗中的一项挑战，需要更多临床证据来指导治疗策略的选择。本研究回顾了TNBC的传统治疗方式以及可用的新辅助化疗（NACT）方案的选择。还综述了优化NACT方案的研究进展，并强调了这种乳腺癌亚型治疗的独特性，以便为TNBC治疗的临床实践和研究提供参考。
相似文献
1
Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.三阴性乳腺癌新辅助治疗的治疗模式与进展
Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340. eCollection 2022 Jul.
2
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.新辅助化疗治疗的三阴性乳腺癌患者的BRCA突变状态：治疗决策中的关键作用
Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14194571.
3
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.三阴性乳腺癌的新辅助治疗：铂类化疗、PARP 和免疫检查点抑制剂活性和疗效的潜在预测生物标志物。
Expert Opin Pharmacother. 2020 Apr;21(6):687-699. doi: 10.1080/14656566.2020.1724957. Epub 2020 Feb 13.
4
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.三阴性乳腺癌的展望：当前治疗策略、未满足的需求及未来治疗的潜在靶点
Cancers (Basel). 2020 Aug 24;12(9):2392. doi: 10.3390/cancers12092392.
5
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.三阴性乳腺癌新辅助治疗中的争议问题
Ther Adv Med Oncol. 2019 Nov 1;11:1758835919882581. doi: 10.1177/1758835919882581. eCollection 2019.
6
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.基于 qRT-PCR 的 DNA 同源重组相关 4 基因评分预测三阴性乳腺癌对铂类新辅助化疗的病理完全缓解。
Breast Cancer Res Treat. 2022 Jan;191(2):335-344. doi: 10.1007/s10549-021-06442-x. Epub 2021 Nov 19.
7
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.三阴性乳腺癌的现行治疗策略：手术、放疗和化疗的适当结合。
Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3.
8
Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.早期三阴性乳腺癌：免疫疗法的治疗作用及病理完全缓解的预后价值
Explor Target Antitumor Ther. 2024;5(1):232-250. doi: 10.37349/etat.2024.00215. Epub 2024 Feb 28.
9
BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.BRCA 基因突变状态是三阴性乳腺癌铂类化疗的有前途的预测生物标志物。
Curr Drug Targets. 2020;21(10):962-973. doi: 10.2174/1389450121666200203162541.
10
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives.三阴性乳腺癌的新辅助治疗策略：“最新进展”与未来展望。
Anticancer Agents Med Chem. 2015;15(1):15-25. doi: 10.2174/1871520614666141019191616.
引用本文的文献
1
The effect of silencing the Tip60 gene on the response to radiotherapy in breast cancer cells.沉默 Tip60 基因对乳腺癌细胞放射治疗反应的影响。
Breast. 2023 Jun;69:507-512. doi: 10.1016/j.breast.2023.04.001. Epub 2023 Apr 13.
2
Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance.对氧磷酶 2 在三阴性乳腺癌中上调，并促进肿瘤进展和化疗耐药性。
Hum Cell. 2023 May;36(3):1108-1119. doi: 10.1007/s13577-023-00892-9. Epub 2023 Mar 10.
3
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.HER2 低表达状态对临床 HER2 阴性乳腺癌新辅助化疗反应的影响。
Clin Transl Oncol. 2023 Jun;25(6):1673-1681. doi: 10.1007/s12094-022-03062-9. Epub 2022 Dec 31.
4
Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.基于 PD-1/PD-L1 的免疫疗法治疗转移性三阴性乳腺癌的原理和临床研究进展。
Int J Mol Sci. 2022 Aug 10;23(16):8878. doi: 10.3390/ijms23168878.
本文引用的文献
1
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.三阴性、早期高危及局部晚期乳腺癌新辅助治疗（无论是否联合阿替利珠单抗）的病理完全缓解（pCR）：NeoTRIP米开朗基罗随机研究
Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17.
2
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects.免疫检查点抑制剂在三阴性乳腺癌治疗中的应用：前景广阔。
Front Oncol. 2021 Feb 25;10:600573. doi: 10.3389/fonc.2020.600573. eCollection 2020.
3
Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.铂类新辅助化疗用于三阴性乳腺癌：一项系统评价与荟萃分析
J Int Med Res. 2020 Oct;48(10):300060520964340. doi: 10.1177/0300060520964340.
4
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).在 HER2 阴性乳腺癌且同源重组缺陷（GeparOLA 研究）患者中，新辅助紫杉醇/奥拉帕利对比紫杉醇/卡铂。
Ann Oncol. 2021 Jan;32(1):49-57. doi: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21.
5
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.早期三阴性乳腺癌患者新辅助阿替利珠单抗联合序贯纳武利尤单抗和基于蒽环类的化疗与安慰剂和化疗相比：一项随机、双盲、III 期试验（IMpassion031）。
Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20.
6
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.三阴性乳腺癌的新辅助治疗：最新进展与挑战
Cancers (Basel). 2020 May 29;12(6):1404. doi: 10.3390/cancers12061404.
7
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.评估乳腺癌间质肿瘤浸润淋巴细胞（sTILs）时的陷阱。
NPJ Breast Cancer. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020.
8
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.帕博利珠单抗联合化疗作为高危早期三阴性乳腺癌的新辅助治疗：来自 1b 期开放标签、多队列 KEYNOTE-173 研究的结果。
Ann Oncol. 2020 May;31(5):569-581. doi: 10.1016/j.annonc.2020.01.072. Epub 2020 Feb 14.
9
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.TNFR2+ TILs 与三阴性乳腺癌患者的生存改善显著相关。
Cancer Immunol Immunother. 2020 Jul;69(7):1315-1326. doi: 10.1007/s00262-020-02549-0. Epub 2020 Mar 20.
10
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
Zotero 插件